- Home
- HEQ vs MNPR Comparison
HEQ vs MNPR Comparison
Compare HEQ & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- MNPR
- Stock Information
- Founded
- HEQ 2011
- MNPR 2014
- Country
- HEQ United States
- MNPR United States
- Employees
- HEQ N/A
- MNPR N/A
- Industry
- HEQ Investment Managers
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- HEQ Finance
- MNPR Health Care
- Exchange
- HEQ Nasdaq
- MNPR Nasdaq
- Market Cap
- HEQ 132.3M
- MNPR 113.5M
- IPO Year
- HEQ N/A
- MNPR 2019
- Fundamental
- Price
- HEQ $10.42
- MNPR $30.68
- Analyst Decision
- HEQ
- MNPR Strong Buy
- Analyst Count
- HEQ 0
- MNPR 3
- Target Price
- HEQ N/A
- MNPR $27.33
- AVG Volume (30 Days)
- HEQ 43.1K
- MNPR 93.6K
- Earning Date
- HEQ 01-01-0001
- MNPR 11-08-2024
- Dividend Yield
- HEQ 9.78%
- MNPR N/A
- EPS Growth
- HEQ N/A
- MNPR N/A
- EPS
- HEQ N/A
- MNPR N/A
- Revenue
- HEQ N/A
- MNPR N/A
- Revenue This Year
- HEQ N/A
- MNPR N/A
- Revenue Next Year
- HEQ N/A
- MNPR N/A
- P/E Ratio
- HEQ N/A
- MNPR N/A
- Revenue Growth
- HEQ N/A
- MNPR N/A
- 52 Week Low
- HEQ $9.08
- MNPR $1.55
- 52 Week High
- HEQ $11.84
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- HEQ 30.72
- MNPR 76.63
- Support Level
- HEQ $10.90
- MNPR $20.16
- Resistance Level
- HEQ $11.06
- MNPR $25.97
- Average True Range (ATR)
- HEQ 0.10
- MNPR 2.75
- MACD
- HEQ -0.07
- MNPR 0.41
- Stochastic Oscillator
- HEQ 0.00
- MNPR 90.25
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.